|
Senate FDA Reform Bill More Flash Than Action, Expert Says
A bulky new Senate bill intended to boost transparency of FDA operations is merely a splashy suite of ornamental add-ons that lack key metrics for success, a former agency executive says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives